Recent Updates
Recently added Catalysts
ABBV

Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended

Key Takeaway: Guidance Including the Impact of Acquired IPR D and Milestones Expense (in millions, except per share data) Quarter Ended December 31, 2022 Full-Year Ended December 31, 2022 Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range Acquired IPR D and Milestones Expens

Full Press Release Details

Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data) Quarter Ended December 31, 2022 Full-Year Ended December 31, 2022
Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range
Low High Low High
Previously announced guidance excluding Q4 2022 acquired IPR D and milestones expense $ - $ 3.65 $ 3.69 $ 454 $ 13.84 $ 13.88
Q4 2022 acquired IPR D and milestones expense 243 (0.14) (0.14) 243 (0.14) (0.14)
Guidance including Q4 2022 acquired IPR D and milestones expense $ 243 $ 3.51 $ 3.55 $ 697 $ 13.70 $ 13.74
Last updated: Dec 31, 2022